ALCON AG ALC 深 沪
等待开盘 12-18 09:30:00 美东时间
79.795
+0.775
+0.98%
华盛通- 最 高79.905
- 今 开78.98
- 成交量 55.23万股
- 最 低 78.96
- 昨 收 79.02
- 总市值 394.99亿
- 52周最高 98.8664
- 市盈率 静 39.00
- 换手率 0.11%
- 52周最低 71.55
- 委 比 -50.00%
- 总股本 4.95亿
- 历史最高 100.7664
- 量 比 0.94
- 振 幅 1.20%
- 历史最低 38.2212
- 每 手 1
- 风险率 6.38%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 绩后分化！甲骨文遭14家大行集体下调目标价；新思科技、Planet获多家机构上调目标价！
今日重点评级关注：HC Wainwright & Co.：维持Moleculin Biotech"买入"评级，目标价从4美元升至22美元；HC Wainwright & Co.：上调Soluna Holdings评级至"买入"，目标价5美元
12-12 10:24
Broadwood Slams STAAR–Alcon Deal as Flawed and Unfair to Shareholders
Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood," "we," "us" or "our") today reacted to the proxy statement supplement filed by STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA) with
12-11 20:12
Broadwood Partners, 30.2% Stake Holders, Opposes Alcon's STAAR Surgical Acquisition; Says Calls Price Bump "Insufficient" And Sale Process Deeply Flawed
Notes That Price Bump Is Further Evidence That the Original Sale Process Was Horribly Flawed and Failed to Maximize Shareholder ValueNew Price Is Approximately Half the Price Offered by Alcon Twice in 2024; STAAR's
12-10 02:05
美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
11-25 10:27
BTIG Reiterates Buy on Alcon, Maintains $91 Price Target
BTIG analyst Ryan Zimmerman reiterates Alcon (NYSE:ALC) with a Buy and maintains $91 price target.
11-24 18:42
美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
11-14 10:43
美股大行评级 | 富国银行上调AMD目标价升至345美元；花旗上调礼来目标价升至1500美元；巴克莱上调腾讯音乐目标价升至28美元
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从12美元升至15美元；Canaccord Genuity：维持Viking Therapeutics"买入"评级，目标价从106美元升至107美元
11-13 09:58
New Eye Tech Is Booming For Alcon, Stock Soars
Metagenomi reports MGX-001 achieved functional FVIII activity in primates, supporting clinical plans for its hemophilia A gene therapy program.
11-13 00:30
美股大行评级 | CoreWeave、Monday遭美银、小摩等多家大行下调目标价；中金首予Nebius "跑赢大市"评级，目标价143美元
今日重点评级关注：Piper Sandler：维持MeiraGTx Hldgs"超配"评级，目标价从28美元升至30美元；RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从26美元升至32美元
11-12 11:43
